Excellos Opens Cutting-Edge Cell Therapy GMP Manufacturing Facility in Downtown San Diego

cell therapy GMP manufacturing

June 27, 2023; San Diego, California – Excellos Opens Cutting-Edge Cell Therapy GMP Manufacturing Facility in Downtown San Diego. Cell Therapy GMP Manufacturing Facility Excellos, a full-service contract development and manufacturing organization (CDMO) for cell therapy, proudly announces the opening of their cell therapy GMP manufacturing facility in the heart of downtown San Diego. The facility […]

Excellos Launches ‘Excellos 360’ Alongside RUO and GMP Product Portfolio to Reduce Clinical Response Variability

Excellos 360

The central aims of Excellos 360 are to reduce clinical response variability and possibly improve outcomes, lower safety liability by allowing effectiveness in lower dosages and reducing the cost of goods associated with advanced therapies. January 17, 2023; San Diego, California – Excellos, the California-based, full-service CDMO, has today announced the launch of ‘Excellos 360’, […]

Single-Cell Analysis of T Cells – Improved Prediction of Disease Risk

Single-Cell analysis T-Cells Excellos Blog

The La Jolla researchers are studying how small changes in gene expression can influence the function of immune cells during infection. Single-cell analysis was performed on activated CD4+ T cells from 89 healthy donors. It turns out that the old adage of “one gene, one protein” is not precisely true. In reality, as research on […]

Stem Cell Transduction Efficiency – Managing Donor Variance

Managing Donor Variance in Stem Cell Transduction Efficiency

Gene therapy, and in particular, therapy involving genetically modified stem cells, is one of the most promising methods for treating genetic disease and defects, and has therefore become a popular focus of research and development. In recent years, using adenoviral vectors to deliver modified genes has become standard practice. Adeno-associated viruses (AVVs) are easy to […]

Single-Cell Immune Profiling Reveals Remarkable Changes Associated with COVID-19

single-cell immune profiling reveals immune changes associated with COVID-19

Researchers at the La Jolla Institute for Immunology cite using Excellos sourced healthy donor starting material to carry out single-cell immune profiling for their research on severe COVID-19. [1] Great strides have been made in fighting the SARS-CoV-2 virus, the most noteworthy being the development and distribution of the COVID-19 vaccine. However, we must keep […]

Trogocytosis – A Case of T cell Identity Theft Offers Essential Clue to Solving MS

Trogocytosis - A Case of T-cell Identity Theft

A case of immune T cell identity theft (trogocytosis) gave German scientists the vital clue they needed to understand a key mechanism behind the development of multiple sclerosis (MS). In a recently published paper, scientists at the Institute of Neuropathology in Gottingen, Germany, describe new research that could help doctors treat MS. [1] The key […]

Efficient Isolation of Antigen-Specific B Cells

Efficient Isolation of Antigen-Specific B Cells

Scientists at Scripps Research Center in La Jolla are working to streamline monoclonal antibody vaccine development by devising more efficient ways to screen for rare B antigen-specific B cells. [1] Today, monoclonal antibodies (mAbs) are at the forefront of vaccine research as scientists continue to develop new treatments to fight cancer, autoimmunity, and infectious disease. […]

Cancer Immunotherapy – High Precision & Remote-Controlled

High Precision Remote-Controlled Cancer Immunotherapy

Researchers at UCSD and Memorial Sloan Kettering Cancer Center used Excellos healthy donor starting material to carry out a fascinating study on ultrasonic activation of cancer immunotherapy. CAR-T cell therapy is a paradigm shifting therapeutic with the potential to have an immense impact on cancer treatment options. The number of CAR-T therapies in clinical trial […]

NK cell therapy – Excellos Cells Aid Discovery of Key Cancer Killing Target

NK cell therapy holds the promise of new therapeutics for underserved cancer indications

NK cell therapy holds the promise of new therapeutics for underserved cancer indications. A recent publication in Nature Communications uses Excellos sourced cellular starting materials for research on the mechanisms behind NK cell cytotoxicity. [1] The capacity for cancer cells to avoid immune detection is notorious. Normally, cells that are faulty, diseased, or reaching the […]